Accelerating the discovery of future cures with Exscalate
Exscalate is the most advanced intelligent supercomputing platform for drug screening, and the largest enumerated chemical library in the world for preclinical and clinical candidate identification. The platform has transformed our drug discovery process — making it faster, more efficient, and less expensive.
Partnering with the scientific community
We are deeply committed to partnering with the scientific community to unlock value from drug and technology developments and advance discoveries into new treatments. As such, Exscalate adopts an open innovation approach with our partners, including academic institutions, biotech start-ups and industry players.
Our strategic partnerships have already led to the identification of new molecules presently in advanced clinical development. For instance, in 2020, Exscalate, in collaboration with Aramis Biosciences, rapidly identified a proprietary molecule for treating dry eye disease. From target identification to an investigational new drug, approval took just 14 months. The power of Exscalate was also leveraged by Exscalate4CoV, a public-private consortium of European partners, in the fight against COVID-19. In just four months, a low molecular weight negative allosteric modulator, Raloxifene, was identified and successfully entered Phase III clinical trials.
Find out more about how Exscalate is accelerating drug discovery